Ardelyx (ARDX) Finishes Phase 3 Enrollment Early As Patent Protection Nears

• Ardelyx (NasdaqGM: ARDX) completed enrollment ahead of schedule in its Phase 3 ACCEL trial of IBSRELA for chronic idiopathic constipation.
• The ACCEL study evaluates IBSRELA as a potential treatment option for adults with chronic idiopathic constipation beyond its existing indication.
• The business received notice of an upcoming US patent issuance covering commercial formulations of IBSRELA and XPHOZAH.
• Early completion of ACCEL enrollment and the pending IBSRELA and XPHOZAH patent sit alongside broader findings from Ardelyx research coverage. Take a look at 1 warning sign we have identified for Ardelyx.

Consider widening your watchlist to other healthcare developers that intersect with AI tools and data-driven drug discovery through 38 healthcare AI stocks.

Ardelyx focuses on discovering and commercializing therapies for unmet medical needs in areas like kidney and gastrointestinal disease, so progress in IBSRELA and XPHOZAH aligns directly with its core research effort. As a mid-cap US biotech player with a market value of about $822.0 million, the firm competes with larger drug developers while still operating with a focused pipeline.

4 things going right for Ardelyx that this headline doesn't cover.

Why ACCEL and new patents matter for the Ardelyx thesis

This update tightens the Ardelyx story around two concrete levers investors already care about. Faster ACCEL recruitment supports the idea that IBSRELA could have a broader addressable pool in chronic idiopathic constipation, which reinforces the revenue catalyst many shareholders are watching. The upcoming US patent for IBSRELA and XPHOZAH reinforces protection around the current commercial portfolio, putting more weight on how effectively the existing products can be monetized rather than on new assets. In the context of quarterly revenue of US$127.66 million and a very small net loss of US$0.737 million, investors now have clearer evidence that clinical execution and intellectual property are pulling in the same direction.

For this to meaningfully affect the investment case, two things need close attention. The first is ACCEL topline data in the second half of 2027, which will test whether IBSRELA can support a CIC label. The second is how IBSRELA and XPHOZAH sales trend through 2027 while the patent protection is in place, including whether Ardelyx can turn the recent US$55.06 million nine month loss into consistent profitability.

Add Ardelyx to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com